Pharmaceutical approval update.
Extended-release carbinoxamine maleate oral suspension (Karbinaler) for allergicrhinitis; brinzolamide 1.0%/brimonidine tartrate 0.2% ophthalmic suspension (simbrinza) for open-angle glaucoma and ocular hypertension; and cysteamine bitartrate (Procysbi) for nephropathic cystinosis.
Marvin M
MM
Goldenberg